Project Grant R44AR078669

This $479,560 Project Grant awarded by the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development supports the initiation, enrollment, and completion of a Phase 3 clinical trial to evaluate the safety and efficacy of PTX-022 (topical sirolimus gel 3.9% w/w) for the treatment of microcystic lymphatic malformations, a rare and serious condition with no FDA-approved therapies. The funding will also support the New Drug Application (NDA) submission and FDA approval process...

This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports the development of a cloud-based, customer-responsive dosimetry tool for alpha-particle emitting radiopharmaceutical therapies. Radiopharmaceutical Imaging And Dosimetry, LLC will receive $898,497 over the project period from August 2024 to July 2026 to implement a macro-to-micro (M2M) dosimetry methodology that derives microscale activity...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of Fibroplate Inc.'s Fibrinogen-Coated Albumin Nanospheres (FAS) technology for mitigating radiation-induced wound healing impairment in breast cancer patients. The $772,940 award will fund a preclinical assessment to demonstrate FAS's ability to accelerate surgical wound healing after radiotherapy and evaluate its safety profile in a murine breast cancer model. This...

The National Cancer Institute (NCI) awarded a $644,034 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a nanoparticle-based drug delivery platform that uses radiation to control the release of chemotherapy payloads within irradiated tumor tissue. The project aims to expand the therapeutic window of chemoradiation by improving local disease control while mitigating...

This Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), provides $1,493,635 to Sinopia Biosciences Inc. to develop a novel orally bioavailable compound that selectively inhibits a specific target domain for treating radiation-induced oral mucositis. The award supports preclinical research to characterize this compound in a fractionated radiation model of oral mucositis, with the goal...

This Project Grant award from the National Institutes of Health (NIH) under the Research Infrastructure Programs (CFDA 93.351) provides $563,028 to Kommodo Therapeutics LLC to develop engineered gamma delta T cells for systemic treatment of recessive dystrophic epidermolysis bullosa (RDEB). The goal is to engineer gamma delta T cells to produce high levels of the type VII collagen protein that is deficient in RDEB patients, enabling the cells to home to the skin and mucosal tissues and deposit...

The federal Project Grant award R21CA282561, with $219,024 in funding from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395), aims to test the beneficial effects of the CSP7 peptide in inhibiting radiation-induced lung injury (RILI) and resolving radiation-induced pulmonary fibrosis (RIPF) in mice. This research will explore the potential of CSP7 as a novel intervention to protect cancer patients undergoing thoracic radiation therapy from the debilitating side...

The National Institutes of Health (NIH) Office of the Director, under the Trans-NIH Research Support program (CFDA 93.310), awarded a $470,309 Cooperative Agreement to Chromologic LLC, a minority-owned small business in Monrovia, California, to develop a genetically modified probiotic for the localized delivery of a radiation mitigator to the gastrointestinal (GI) tract. The goal is to reduce damage and regenerate tissue after exposure to ionizing radiation, which can lead to hematopoietic or GI...

This $644,622 Project Grant, awarded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), aims to enhance the efficacy of radioligand therapy for metastatic castrate-resistant prostate cancer. The key products and services to be delivered include: Developing a novel method for bone marrow dosimetry by coupling macro/micro Monte Carlo modeling with imaging data on lesion and marrow distribution in spongiosa. Building predictive models to forecast absorbed...

This Project Grant award of $662,516 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to evaluate how fractionated radiation affects the tumor microenvironment to influence passive drug delivery. The key research objectives are: Quantify how local radiation reshapes the tumor microenvironment to impact passive drug delivery in mouse and patient-derived cancer models, using in vivo imaging, multiplexed microscopy, and functional perturbations. Test whether...